Literature DB >> 17891572

Papillary tumour of the pineal region.

T Santarius1, J A Joseph, K T Tsang, D G O'Donovan, R W Kirollos.   

Abstract

Papillary tumour of the pineal region (PTPR) is a relatively new and rare pathological entity, which appears to run a spectrum of clinical courses. We add another case with detailed description of the clinical course documented with serial imaging over the total of 7 years. In accordance with previous reports we recommend total surgical resection with subsequent focal radiotherapy. Clinical and radiological follow up of the entire cerebrospinal axis is mandatory.

Entities:  

Mesh:

Year:  2008        PMID: 17891572     DOI: 10.1080/02688690701583794

Source DB:  PubMed          Journal:  Br J Neurosurg        ISSN: 0268-8697            Impact factor:   1.596


  4 in total

Review 1.  Complete regression of papillary tumor of the pineal region after radiation therapy: case report and review of the literature.

Authors:  Smruti K Patel; Krystal L Tomei; Lana D Christiano; Ada Baisre; James K Liu
Journal:  J Neurooncol       Date:  2011-11-16       Impact factor: 4.130

2.  Neuroradiological follow-up of the growth of papillary tumor of the pineal region: a case report.

Authors:  Alfonso Cerase; Ignazio Maria Vallone; Giovanni Di Pietro; Giuseppe Oliveri; Clelia Miracco; Carlo Venturi
Journal:  J Neurooncol       Date:  2009-06-11       Impact factor: 4.130

3.  Role of surgery, radiotherapy and chemotherapy in papillary tumors of the pineal region: a multicenter study.

Authors:  F Fauchon; M Hasselblatt; A Jouvet; J Champier; M Popovic; R Kirollos; T Santarius; S Amemiya; T Kumabe; D Frappaz; M Lonjon; M Fèvre Montange; A Vasiljevic
Journal:  J Neurooncol       Date:  2013-01-12       Impact factor: 4.130

4.  Bevacizumab is Effective for Recurrent Papillary Tumor of the Pineal Region: First Report.

Authors:  Adam L Cohen; Karen Salzman; Cheryl Palmer; Randy Jensen; Howard Colman
Journal:  Case Rep Oncol       Date:  2013-08-24
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.